NewsBenzingaMoleculin Reports 43% And 36% Complete Remission Rates In Annamycin Phase 2/3 Trial For Relapsed Or Refractory AML Moleculin Reports 43% And 36% Complete Remission Rates In Annamycin Phase 2/3 Trial For Relapsed Or Refractory AML Benzinga 2026.11.04 16:04 (GMT+0) Open on Benzinga Other news RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Raises Price Target to $125 Leerink Partners Maintains Outperform on Cencora, Raises Price Target to $405 RBC Capital Maintains Outperform on Zillow Group, Lowers Price Target to $38 RBC Capital Maintains Sector Perform on Wayfair, Raises Price Target to $128 Leerink Partners Maintains Outperform on CVS Health, Lowers Price Target to $104 RBC Capital Maintains Sector Perform on W.W. Grainger, Raises Price Target to $1582
